Veterinary Medicine Powder CAS 93106-60-6 Enrofloxacin HCl Enrofloxacin

• Varieties: Parasite Disease Prevention Medicine
• Component: Animal
• Type: The First Class
• Pharmacodynamic Influential Factors: Animal Species
• Storage Method: Prevent High or LowTemperature
• Veterinary Reg. No.: 09853
• Model NO.: Enrofloxacin
• Product: Enrofloxacin HCl
• CAS: 204-271-8
• Mf: C19h22fn3o3
• Transport Package: Drum
• Specification: 99%
• Trademark: HS
• Origin: China
• HS Code: 2904201000
• Production Capacity: 100000

Product Description

Product Name: enrofloxacin

Specification: 99%

Cas No: 93106-60-6

Einecs No: 204-271-8 

Molecular formula: C19H22FN3O3

Molecular weight: 359.39

Enrofloxacin HCL is a broad spectrum bactericidal drugs,have special effects on mycoplasma.White on escherichia coli, klebsiella bacillus coli,pseudomonas aeruginosa,salmonella,deformation,haemophilus, kill,pasteurella,streptococcus hemolytic pap coli,s.aureus bacteria, such as have antiseptic effec

 

1. Dogs and Cats

The product is indicated in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

2. Cattle

Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and secondary bacterial infections subsequent to viral conditions (e.g. viral pneumonia) where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

3. Pigs

Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, actinobacillosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and mulifactorial diseases such as atrophic rhinitis and enzootic pneumonia, where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

ANALYTICAL ITEMS	SPECIFICATION	ANALYTICAL RESULTS
Appearance	White Powder	Confirms
PH	4.0-6.0	Confirms
Related substances	≤1.0%	Confirms
Moisture	3.0~4.0%	Confirms
Residue on ignition	no more than 0.2%	Confirms
Heavy metal	no more than 0.001%	Confirms
residual solvent	Conforms to the requirement	Confirms
Assay	98.0%~102.0%	99.5%
Conclusion	Confirms to Enterprise Standard